Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to a potential multibillion ...

W estern drugmakers, including Eli Lilly , Pfizer , and Novo Nordisk , are looking to boost sales of their most innovative and expensive medicines in China, the world’s second-l ...

Six months into Donald Trump’s second term, his administration is at war with the federal judiciary, evading court orders ...

Patients on a combination of toripalimab and RemeGen's anti-HER2 antibody disitamab vedotin fared better than those on a chemotherapy regimen.

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

The dollar fell against a basket of currencies, after President Trump said he would nominate Stephen Miran to temporarily join the Federal Reserve's board of governors. "Miran has expressed skepticism ...

News of a trade secrets leak involving TSMC and an action in Japan against AI startup Perplexity were also among the top ...

Dow Jones Top Company Headlines at 5 AM ET: Intel's CEO, Under Attack From Trump, Is Already at Odds With His Board | Apple ... Intel's CEO, Under Attack From Trump, Is Already at Odds With His Board ...